4
Participants
Start Date
February 8, 2018
Primary Completion Date
September 13, 2018
Study Completion Date
October 19, 2018
Visipaque
100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
Placebos
100 mL saline, followed by a 10 mL saline flush.
UZ Leuven, Leuven
Mount Sinai West, New York
Hospital Universitario Puerta del Mar, Cadiz
Wake Forest Baptist Health, Winston-Salem
University of North Carolina at Chapel Hill Clinical Translational Research Center, Chapel Hill
Jacksonville Center for Clinical Research, Jacksonville
Universal Axon Clinical Research, LLC, Doral
University of South Florida - South Tampa Campus, Tampa
University Hospital, Birmingham
Norton Hospital, Louisville
University of Iowa Hospitals and Clinics, Iowa City
The Duluth Clinic, Ltd., Duluth
Central Arkansas Veteran's Healthcare System, Little Rock
UT Southwestern Medical Center, Dallas
: Aventiv Research Inc., Mesa
Alliance Research Centers, Laguna Hills
Boston University Medical Center/Boston Medical Center, Boston
Rhode Island Hospital, Providence
University of Vermont Medical Center, Burlington
CRCHUM- CHUM Research Center, Montreal
St. Boniface General Hospital, Winnipeg
Oddzial Chirurgii Naczyniowej i Ogolnej, Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu, Bytom
Klinika Kardiochirurgii i Chirurgii Naczyniowej, Uniwersyteckie Centrum Kliniczne, Gdansk
Klinika Chirurgii Naczyniowej i Angiologii, Samodzielny Publiczny Szpital Kliniczny nr 1, Lublin
Oddzial Chirurgii Ogolnej i Naczyn, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznan
Hospital Clinic de Barcelona, Barcelona
Hospital Universitario Son Espases, Palma
St. George's Healthcare NHS Trust, St. George's Hospital, London
Royal Stoke University Hospital, Radiology Department, Stoke-on-Trent
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
GE Healthcare
INDUSTRY